Respiratory drug developer Vectura has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its new inhaled pulmonary treatment being tested by Novartis. The FTSE Small Cap company reported that the European Medicines Agency's CHMP gave its positive opinion about the use of Vectura's QVA149 drug combination, now branded Ultibro Breezhaler, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).Chief Executive Chris Blackwell said the opinion represented "a very important step" towards gaining regulatory approval in Europe. He added that the positive results returned from Novartis' Phase III 'Ignite' program gave Vectura confidence that QVA149 could be the first product of its kind to provide patients benefits in the multi-billion dollar COPD market.QVA149 or Ultibro Breezhaler is a once-daily, fixed-dose combination of long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) bronchodilators.Shares in Vectura were up 8.3% to 91p at 16:14 on Friday. OH